Alpha 2.0
Login Register
» Authors » Elke Gasthuys

Elke Gasthuys

Explore the profile of Elke Gasthuys including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 177
Followers 0
Related Specialties
Pharmacology
Pediatrics
Chemistry
Top 10 Co-Authors
An Vermeulen
Jan Van Bocxlaer
Siska Croubels
Johan Vande Walle
Mathias Devreese
Pieter-Jan De Sutter
Joske Millecam
Pauline De Bruyne
Siegrid De Baere
Gunther Antonissen
Published In
Front Pharmacol
Clin Pharmacokinet
Br J Clin Pharmacol
Pharmaceutics
Drug Metab Dispos
Affiliations
Soon will be listed here.
Recent Articles
1.
Dose-Limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition-A Protocol for an Observational Cohort Study
De Nys L, Barzegar-Fallah A, Lanckmans K, Steurbaut S, Beckwee D, de Haar-Holleman A, et al.
Cancers (Basel) . 2025 Jan; 17(1. PMID: 39796679
: Paclitaxel (PTX), a commonly used chemotherapy for breast cancer (BC), is associated with dose-limiting toxicities (DLTs) such as peripheral neuropathy and neutropenia. These toxicities frequently lead to dose reductions,...
2.
The use of population pharmacokinetics to extrapolate food effects from human adults and beagle dogs to the pediatric population illustrated with ibuprofen as a case
Gasthuys E, Sandra L, Statelova M, Vertzoni M, Vermeulen A
Int J Pharm . 2024 Dec; 669():125015. PMID: 39617191
Oral drug administration is the most convenient route of administration in the pediatric population. However, children are often not fasted when drugs are orally administered, hence potential food-drug interactions might...
3.
A matrix tool to foster patient engagement in children, adolescents and young adults: report from a multistakeholder workshop
Cavaller-Bellaubi M, Degraeuwe E, Walle J, Gasthuys E, Prytula A
Res Involv Engagem . 2024 Nov; 10(1):125. PMID: 39604985
Background: Patient engagement has become increasingly important in drug development, yet structured guidance to engage children (2-11 years old), adolescents (12-17 years old), and young adults (18-24 years old) is...
4.
Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study
Degraeuwe E, Gasthuys E, Snauwaert E, Dossche L, Prytula A, Dehoorne J, et al.
Pediatr Nephrol . 2024 Oct; 40(3):797-809. PMID: 39466390
Background: Over the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions....
5.
Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults
De Sutter P, Hermans E, De Cock P, Van Bocxlaer J, Gasthuys E, Vermeulen A
Clin Pharmacokinet . 2024 Jul; 63(7):965-980. PMID: 38955946
Background And Objective: The interstitial fluid of tissues is the effect site for antibiotics targeting extracellular pathogens. Microdialysis studies investigating these concentrations in muscle and subcutaneous tissue have reported notable...
6.
Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study
Lootens O, De Boevre M, Gasthuys E, De Saeger S, Van Bocxlaer J, Vermeulen A
Toxins (Basel) . 2024 Jun; 16(6). PMID: 38922153
Physiologically based pharmacokinetic (PBPK) models were utilized to investigate potential interactions between aflatoxin B1 (AFB1) and efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor drug and inducer of several CYP enzymes,...
7.
The Use of Population Pharmacokinetics to Extrapolate Food Effects from Human Adults and Beagle Dogs to the Pediatric Population Illustrated with Paracetamol as a Test Case
Gasthuys E, Sandra L, Statelova M, Vertzoni M, Vermeulen A
Pharmaceuticals (Basel) . 2024 Jan; 17(1). PMID: 38256887
To date, food-drug interactions in the pediatric population remain understudied. The current food effect studies are mostly performed in adults and do not mimic the real-life situation in the pediatric...
8.
Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis
Gasthuys E, van Ovost J, Vande Casteele S, Cosyns S, Ceelen W, Van Bocxlaer J, et al.
J Chromatogr B Analyt Technol Biomed Life Sci . 2024 Jan; 1233:123980. PMID: 38215697
Irinotecan (CPT-11), an antineoplastic drug, is used for the treatment of colorectal and pancreatic cancer due to its topoisomerase I inhibitory activity. CPT-11 is a prodrug which is converted to...
9.
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
De Sutter P, Gasthuys E, Vermeulen A
J Pharmacokinet Pharmacodyn . 2023 Nov; 51(6):639-651. PMID: 37952005
Physiologically based pharmacokinetic (PBPK) models can be used to leverage physiological and in vitro data to predict monoclonal antibody (mAb) concentrations in serum and tissues. However, it is currently not...
10.
Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function
Sandra L, Degraeuwe E, De Bruyne P, De Baere S, Croubels S, Van Bocxlaer J, et al.
Br J Clin Pharmacol . 2023 Oct; 90(2):504-515. PMID: 37864281
Aims: Lisinopril, an angiotensin-converting enzyme inhibitor, is a frequently prescribed antihypertensive drug in the paediatric population, while being used off-label under the age of 6 years in the USA and...